Infectious Disease Therapeutics Market Regional Analysis:
North America Market Insights
North America infectious disease therapeutics market will account for a 42.1% revenue share by 2035. Factors such as the aging population, lucrative healthcare expenditure, and the presence of strong research and development infrastructure drive demand for technically advanced diagnostics tools, and treatments.
U.S., is the largest infectious disease therapeutics market in North America, owing to the existence of prominent players and robust pharmaceuticals, research institutions, and hospital infrastructure. The rising burden of infectious diseases has resulted in increasing demand for advanced therapeutics. Leading companies and local bodies are focused on developing novel therapeutics and tools to cater to this surging demand.
Canada is likely to be the fastest-growing country followed by the U.S. owing to its strong healthcare structure, high disposable incomes, favorable reimbursement policies, and adoption of high-tech diagnostics tools. For instance, the Vaccine and Infectious Disease Organization (VIDO) is expanding its expertise and infrastructure as Canada’s center for pandemic research by adding a new vaccine development center with containment level 4 capacity.
APAC Market Insights
The infectious disease therapeutics market in Asia Pacific is expected to witness steady growth during the forecast period attributable to a rise in infectious disease cases, financial aid by the government, and rapid adoption of advanced technologies.
In India, the market is driven by its large population, and continuous local government spending in advancing hospital facilities and infrastructure. With concern to provide healthcare benefits to every corner of the country making it affordable and accessible. In June 2023, INVEX Health announced to launch of India’s first oral fluid HIV self-test considerably more effective than traditional blood-based test.
